Targeting epigenetic modifiers of androgen receptor activity and toxicity in SBMA
SBMA 中雄激素受体活性和毒性的表观遗传修饰因子
基本信息
- 批准号:9754495
- 负责人:
- 金额:$ 39.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:ATAC-seqAffectAmino AcidsAndrogen ReceptorAndrogensAnimal ModelArginineBindingBiologyBiopsy SpecimenCell Differentiation processCellsCessation of lifeChIP-seqConsensusCultured CellsCytosolDNA BindingDiseaseEpigenetic ProcessFutureGene ExpressionGenesGeneticGenetic TranscriptionGlutamineGoalsHormonesInterventionKennedy SyndromeKnock-inKnock-in MouseLengthLysineMediatingMethylationModelingModificationMolecularMotor NeuronsMusMuscleMuscle FibersNerve DegenerationNeuromuscular DiseasesNuclear TranslocationPathogenesisPathologyPathway interactionsPatientsPeripheralPharmacologyPhosphorylationPost-Translational Protein ProcessingPreparationProcessProtein MethylationProtein-Arginine N-MethyltransferaseReceptor GeneRegulationResearchSerineSerumSiteSkeletal MuscleStanoloneTestingTestosteroneTissuesToxic effectTransactivationTransgenic OrganismsValidationandrogen sensitivebaseflygain of functionknock-downmalemouse modelneuromuscularneurotoxicitynew therapeutic targetnovelnovel therapeutic interventionpolyglutaminepromoterprostate cancer cellreceptor functionrecruitskeletal muscle wastingspinal and bulbar muscular atrophytranscriptome sequencing
项目摘要
Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disorder characterized by loss
of lower motor neurons and skeletal muscle atrophy. SBMA is caused by CAG expansions (>38
repeats) encoding a polyglutamine (polyQ) tract in the androgen receptor (AR) gene. The
disease fully manifests in males, as they have high levels of androgens in the serum. PolyQ-AR
is converted to a toxic species upon binding to androgens, testosterone and dihydrotestosterone
(DHT).
We propose to identify the genes involved in regulating polyQ-AR-mediated toxicity and
advance our understanding about the molecular mechanisms underlying SBMA pathogenesis.
The main objective of current R21 application is to determine that transcriptional co-regulators
of AR mediate the toxic gain-of-function (GOF) of polyQ-AR. We hypothesize that two AR
transcription co-regulators, namely protein arginine methyltransferase 6 (PRMT6) and lysine
demethylase 1 (LSD1), synergistically cooperate to enhance the toxic GOF of polyQ-AR by
changing its transcriptional activity. Our hypothesis is based on our observations that post-
translational modifications (phosphorylation and methylation)) of AR are important determinant
of the toxicity. We will utilize well-characterized mouse models of SBMA (transgenic AR100Q
and knock-in AR113Q mice) that show hormone- and glutamine length–dependent
neuromuscular weakness, muscle pathology, and early death. SBMA transgenic and knock-in
mice represent good models to study disease pathogenesis and to test pharmacologic
intervention. We propose to determine how co-regulators of polyQ-AR function in SBMA. We
expect to determine how AR function is regulated in skeletal muscle and dysregulated in SBMA.
脊柱和鳞茎肌肉萎缩(SBMA)是一种神经肌肉疾病,其特征是丧失
低运动神经元和骨骼肌萎缩的。 SBMA是由CAG扩展引起的(> 38
重复序列)编码雄激素受体(AR)基因中的聚谷氨酰胺(polyq)。
疾病在雄性中完全表现出来,因为它们在血清中具有高水平的雄激素。 polyq-ar
在与雄激素,睾丸激素和二氢睾丸激素结合后转化为有毒物种
(DHT)。
我们建议确定调节PolyQ-AR介导的毒性和
促进我们对SBMA发病机理的分子机制的理解。
当前R21应用的主要目的是确定转录共同调节器
AR的介导PolyQ-AR的功能功能获得(GOF)。我们假设两个AR
转录共同调节剂,即蛋白精氨酸甲基转移酶6(PRMT6)和赖氨酸
脱甲基酶1(LSD1),协同坐标以增强PolyQ-AR的毒性GOF
改变其转录活动。我们的假设是基于我们的观察结果
AR的翻译修饰(磷酸化和甲基化))是重要的确定剂
我们将利用SBMA的特征良好的小鼠模型(转基因AR100Q)
和敲入AR113Q小鼠)显示马和谷氨酰胺的长度依赖性
神经肌肉无力,肌肉病理学和早期死亡。 SBMA转基因和敲门
小鼠代表了研究疾病发病机理和测试药学学的良好模型
干涉。我们建议确定PolyQ-AR功能在SBMA中的共同调节剂。我们
期望确定在骨骼肌中如何调节AR功能并在SBMA中调节失调。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Skeletal Muscle Pathogenesis in Polyglutamine Diseases.
- DOI:10.3390/cells11132105
- 发表时间:2022-07-03
- 期刊:
- 影响因子:6
- 作者:Marchioretti, Caterina;Zuccaro, Emanuela;Pandey, Udai Bhan;Rosati, Jessica;Basso, Manuela;Pennuto, Maria
- 通讯作者:Pennuto, Maria
Clenbuterol-sensitive delayed outward potassium currents in a cell model of spinal and bulbar muscular atrophy.
脊髓和延髓肌萎缩细胞模型中克伦特罗敏感的延迟外向钾电流。
- DOI:10.1007/s00424-021-02559-6
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Martínez-Rojas,VladimirA;Arosio,Daniele;Pennuto,Maria;Musio,Carlo
- 通讯作者:Musio,Carlo
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Udai B Pandey其他文献
Udai B Pandey的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Udai B Pandey', 18)}}的其他基金
Identifying the molecular mechanisms of GEMIN5 mutations in a novel cerebellar ataxia syndrome
鉴定新型小脑共济失调综合征中 GEMIN5 突变的分子机制
- 批准号:
10753403 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
- 批准号:
9303039 - 财政年份:2017
- 资助金额:
$ 39.73万 - 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
- 批准号:
9230443 - 财政年份:2014
- 资助金额:
$ 39.73万 - 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
- 批准号:
9014564 - 财政年份:2014
- 资助金额:
$ 39.73万 - 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
- 批准号:
8811504 - 财政年份:2014
- 资助金额:
$ 39.73万 - 项目类别:
Cellular and Molecular Mechanisms of FUS-related ALS/FTD
FUS相关ALS/FTD的细胞和分子机制
- 批准号:
10370356 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
Cellular and Molecular Mechanisms of FUS-related ALS/FTD
FUS相关ALS/FTD的细胞和分子机制
- 批准号:
9901635 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
Cellular and Molecular Mechanisms of FUS-related ALS/FTD
FUS相关ALS/FTD的细胞和分子机制
- 批准号:
9763021 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
- 批准号:
8529133 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
Cellular and Molecular Mechanisms of FUS-related ALS/FTD
FUS相关ALS/FTD的细胞和分子机制
- 批准号:
10582582 - 财政年份:2013
- 资助金额:
$ 39.73万 - 项目类别:
相似国自然基金
低蛋白日粮脂肪和蛋白质互作影响氨基酸消化率的机制
- 批准号:32302793
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
关键非催化氨基酸残基影响新型GH43家族双功能酶底物特异性的机制研究
- 批准号:32301052
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
孕期母体支链氨基酸代谢紊乱和子代支链氨基酸代谢酶基因遗传变异联合作用对儿童神经行为发育影响的队列研究
- 批准号:82373581
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
影响植物磷砷选择性吸收关键氨基酸位点的挖掘及分子机制研究
- 批准号:42307009
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
RET基因634位点不同氨基酸改变对甲状腺C细胞的影响与机制研究
- 批准号:82370790
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
相似海外基金
Interrogating the roles of canonical versus variant histone H3 in genome function during aging
探讨经典组蛋白 H3 与变异组蛋白 H3 在衰老过程中基因组功能中的作用
- 批准号:
10677916 - 财政年份:2023
- 资助金额:
$ 39.73万 - 项目类别:
Understanding methionine metabolism and its therapeutic potential in cancer
了解蛋氨酸代谢及其在癌症中的治疗潜力
- 批准号:
10554637 - 财政年份:2022
- 资助金额:
$ 39.73万 - 项目类别:
Defining the role of the BCL7 subunit of mammalian SWI/SNF chromatin remodeling complexes in human cancer
确定哺乳动物 SWI/SNF 染色质重塑复合物的 BCL7 亚基在人类癌症中的作用
- 批准号:
10604291 - 财政年份:2022
- 资助金额:
$ 39.73万 - 项目类别:
Posttranslational Regulation of FOXA1 in Breast Cancer
FOXA1 在乳腺癌中的翻译后调控
- 批准号:
10504308 - 财政年份:2022
- 资助金额:
$ 39.73万 - 项目类别:
Functional validation of sequence variants affecting neurodevelopmental and craniofacial phenotypes
影响神经发育和颅面表型的序列变异的功能验证
- 批准号:
10701310 - 财政年份:2022
- 资助金额:
$ 39.73万 - 项目类别: